NAMS
NewAmsterdam Pharma Co N.V. · Healthcare · Market cap $2.6B
Insiders sold $7.6M net in the last 90 days ·3 sellers, 1 buyer· latest Form 4 filed Oct 2, 2026
Insider Buying
$227K
reported purchases (SEC code P)
Insider Selling
$63.3M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Oct 2, 2026
Kastelein Johannes Jacob Pieter
NewAmsterdam Pharma Co N.V. (NAMS) has 28 SEC Form 4 filings (80 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Oct 2, 2026.
Inside the rolling window, 6 insiders at NewAmsterdam Pharma Co N.V. reported 1 open-market purchase totaling $227K and 29 open-market sales totaling $63.3M. The most active filer is Chief Accounting Officer Kooij Louise Frederika with 11 filings. Insiders have net sold $11.1M over the trailing 6 months. The most recent open-market filing is a sale of 50,246 shares by Chief Scientific Officer Kastelein Johannes Jacob Pieter, dated Sep 30, 2026, worth $1.3M.
- Industry:Biotechnology
- CEO:Michael Harvey Davidson Facp.
- Employees:100
- HQ:Naarden, NH, NL
- IPO:2021-02-09
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Scientific Officer | Sale | 50,246 | $1.3M | Oct 2 | -7.4% | SEC ↗ | |
Davidson Michael H.First in 7 months | Chief Executive Officer | Purchase | 10,000 | $227K | Sep 15 | +1.6% | SEC ↗ |
| Director | Sale | 1,600 | $41K | Sep 9 | -5.7% | SEC ↗ | |
Kastelein Johannes Jacob PieterFirst in 6 months | Chief Scientific Officer | Sale | 125,000 | $3.4M | Aug 25 | -21.4% | SEC ↗ |
| Chief Accounting Officer | Sale | 105,000 | $3.2M | Jul 22 | -32.2% | SEC ↗ | |
| Chief Accounting Officer | Sale | 40,000 | $1.2M | Jun 24 | -34.1% | SEC ↗ | |
Kooij Louise FrederikaFirst in 4 months | Chief Accounting Officer | Sale | 65,000 | $2.3M | May 27 | -41.2% | SEC ↗ |
| Director | Sale | 44,619 | $1.4M | Mar 12 | — | SEC ↗ | |
LANGE LOUIS GFirst filing | Director | Sale | 28,186 | $829K | Mar 10 | — | SEC ↗ |
| Chief Scientific Officer | Sale | 104,467 | $3.2M | Mar 9 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 94,124 | $2.9M | Mar 9 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 101,409 | $3.1M | Mar 9 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 443,707 | $14.8M | Mar 2 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 64,708 | $2.3M | Feb 26 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 58,253 | $2.1M | Feb 26 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 183,332 | $6.2M | Feb 26 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 45,481 | $1.6M | Feb 24 | — | SEC ↗ | |
| Chief Accounting Officer | Sale | 39,816 | $1.3M | Jan 29 | — | SEC ↗ | |
| Chief Accounting Officer | Sale | 32,612 | $1.0M | Jan 29 | — | SEC ↗ | |
| Chief Accounting Officer | Sale | 38,172 | $1.3M | Jan 27 | — | SEC ↗ | |
| Chief Accounting Officer | Sale | 34,400 | $1.1M | Jan 27 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 60,216 | $1.9M | Jan 22 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 39,784 | $1.3M | Jan 22 | — | SEC ↗ | |
Davidson Michael H.First filing | Chief Executive Officer | Sale | 11,582 | — | Jan 9 | — | SEC ↗ |
| Chief Accounting Officer | Sale | 2,647 | $88K | Jan 7 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does NAMS have?
NewAmsterdam Pharma Co N.V. (NAMS) has 28 SEC Form 4 filings (80 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Oct 2, 2026.
When was the most recent SEC Form 4 filing for NAMS?
The most recent Form 4 filing for NAMS on Tracefour is dated Oct 2, 2026.
Who is the most active insider at NAMS?
The most active SEC Form 4 filer at NAMS in the rolling window is Chief Accounting Officer Kooij Louise Frederika, with 11 filings.
What is the net insider flow at NAMS over the last 6 months?
Over the trailing 180 days, insiders at NAMS have net sold $11.1M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at NAMS in the current window?
Inside the rolling window, insiders at NAMS bought $227K and sold $63.3M based on SEC Form 4 filings.
Can I get alerts for NAMS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at NewAmsterdam Pharma Co N.V. (NAMS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
NewAmsterdam Pharma Co N.V. is in the Healthcare sector.